+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial



The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial



Journal of Hepatology 20(3): 315-320



A reduction in serum enzymes has been already observed by administering ursodeoxycholic acid to patients with chronic active hepatitis. The aim of this study was to assess whether the liver histological activity of inflammation was modified by a 12-month treatment with ursodeoxycholic acid. Thirty-six patients with chronic active hepatitis, fulfilling the inclusion criteria, were admitted to the trial. Patients were randomly allocated to receive double blind either 600 mg/day of ursodeoxycholic acid (Group A: 18 patients) or placebo (Group B: 18 patients). Clinical and biochemical follow-up was performed at 3-month intervals. A percutaneous liver biopsy was performed before and after 1 year of treatment. Histological hepatitis activity was assessed using Knodell's numerical scoring system, while biliary damage was evaluated by an appropriate scoring system. Sixteen and 12 patients in Groups A and B, respectively, completed the clinical and biochemical follow-up. Although a reduction in serum enzymes was found in both groups, multifactorial covariance analysis showed that the reductions in alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transpeptidase were significantly higher in Group A than in Group B. Biochemical remission was not observed in either group. Histological analysis showed a dichotomy between the results from the hepatitis and the biliary components of the disease process. No differences were found in the two groups before or after treatment in histological activity index. which measures the "hepatitic" component. Nor were there any significant differences in baseline values. Furthermore, no relationship was found between changes in biochemical parameters and the histological activity indices. In contrast, the "biliary" component showed significant improvement after ursodeoxycholic acid treatment for certain cholestatic parameters ductular metaplasia, bile duct damage and phenotypic cytokeratin changes. These changes were significantly associated with changes in gamma glutamyl transpeptidase serum levels. This study has confirmed that ursodeoxycholic acid administration in patients with chronic active hepatitis reduces transaminases and gamma glutamyl transpeptidase. The morphological substrate of this biochemical improvement can be traced to the biliary component of the process.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009568243

Download citation: RISBibTeXText

PMID: 7912249

DOI: 10.1016/s0168-8278(94)80001-4


Related references

Effect of ursodeoxycholic acid udca on serum enzymes and liver histology in patients with chronic active hepatitis cah. Journal of Hepatology 13(SUPPL 2): S92, 1991

Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. European Journal of Clinical Pharmacology 40(5): 473-476, 1991

Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: a double-blind controlled trial. Journal of International Medical Research 10(4): 278-282, 1982

Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. Journal of the American College of Cardiology 59(6): 585-592, 2012

Effect of ursodeoxycholic acid on serum liver enzymes and bile acid composition of serum and bile in patients with chronic active hepatitis C. Hepatology 26(4 PART 2): 573A, 1997

One year ursodeoxycholic acid treatment of chronic viral hepatitis in heart transplanted patients Results of a prospective double-blind placebo randomized controlled study in 60 patients. Journal of Hepatology 25(SUPPL 1): 127, 1996

Effect of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis C virus infection. Hepatology Research 39(1): 21-30, 2008

Randomized double blind placebo controlled trial of a 1 month course of prednisolone in chronic type b hepatitis. Gastroenterology 86(5 PART 2): 1324, 1984

A randomised double-blind placebo-controlled trial of prednisolone therapy in HBeAg and HBV DNA positive Chinese patients with chronic active hepatitis B. Journal of Hepatology 12(2): 246-250, 1991

Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Annals of Hepatology 3(3): 108-112, 2004

Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease A double-blind, randomized, placebo-controlled trial. Hepatology 36(4 Part 2): 412A, October, 2002

Effects of ursodeoxycholic acid in association with interferon-alpha-2a on sustained response in chronic hepatitis C A randomized double-blind placebo-controlled study. Gastroenterology 112(4 SUPPL ): A1239, 1997

Ursodeoxycholic acid reduces hepatic allograft rejection after orthotopic liver transplantation A prospective, randomized, placebo-controlled, double-blind trial. Hepatology 22(4 PART 2): 149A, 1995

Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial. Journal of Hepatology 8(1): 7-12, 1989

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis and Rheumatism 48(6): 1667-1675, 2003